Identification of druggable inhibitory immune checkpoints on Natural Killer cells in COVID-19

A Novel Coronavirus from Patients with Pneumonia in China, 2019

(2020) Na Zhu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Functional exhaustion of antiviral lymphocytes in COVID-19 patients

(2020) Meijuan Zheng et al.   Cellular & Molecular Immunology

The Promise and Peril of Natural Killer Cell Therapies in Pulmonary Infection

(2020) Sanjeeth Rajaram et al.   IMMUNITY

Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia

(2020) Fan Wang et al.   JOURNAL OF INFECTIOUS DISEASES

IL-6-induced CD39 expression on tumor-infiltrating NK cells predicts poor prognosis in esophageal squamous cell carcinoma

(2020) Yujia Zheng et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies

(2019) Ivan Perrot et al.   Cell Reports

Trends in clinical development for PD-1/PD-L1 inhibitors

(2019) Jia Xin Yu et al.   NATURE REVIEWS DRUG DISCOVERY

Natural killer cell specificity for viral infections

(2018) Quirin Hammer et al.   NATURE IMMUNOLOGY

Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells

(2018) Pascale André et al.   CELL